Molecular QC for SARS CoV2 + Flu + RSV
Products are for professional/laboratory use only.
AccuPlex™ Reference Material Kits are designed to measure day-to-day performance of the assay, providing both a positive and a negative reference solution.
News
03Feb
Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only)
Products are for professional/laboratory use only.
Being the third¹ liquid biopsy test for Biocartis, the Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only), also marks an important milestone in the partnership with the leading science and technology company Merck².
03Feb
Study using Biocartis’ liquid biopsy BRAF assay shows new option for retreatment of melanoma patients
Products are for professional/laboratory use only.
Biocartis is pleased to announce the publication of an important study [1] by Prof. Dr. Bart Neyns from the University Hospital in Brussels (Belgium) in the clinical oncology journal The Lancet Oncology: ‘A second chance for success with BRAF and MEK inhibitors in Melanoma’.
03Feb
Discover Idylla Explore – offering insight into your molecular data
Products are for professional/laboratory use only.
Get connected and enjoy the advantages of Idylla Explore, a web-based application that allows you to analyze your data by providing:
03Feb
Idylla EGFR Mutation Test (CE-IVD)
Products are for professional/laboratory use only.
Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Test to their core oncology menu, that now covers most known and used oncology biomarkers.
02Feb
Idylla platform – real-time PCR-based molecular diagnostics system
Products are for professional/laboratory use only.
Idylla™, Biocartis’ fully automated, real-time PCR based molecular diagnostics system, is designed to offer fast and easy access to clinical molecular diagnostic information, anywhere and anytime.
02Feb
Standardization of decalcification for optimum molecular testing
Products are for professional/laboratory use only.
Molecular diagnostics are rapidly becoming part of the standard of care for cancer patients. This biomarker based approach serves to select patients likely to benefit from targeted treatment regimens and potentially assists in their inclusion into appropriate clinical trials.
21May
Biocartis Idylla BRAF Mutation Test
Introducing Biocartis Idylla – BRAF molecular results in as little as 90 minutes.
About 50 percent of all melanomas harbor mutations in the BRAF oncogene. Idylla™ BRAF Mutation Test detects BRAF mutations directly from FFPE tissue sections in 90 minutes with less than 2 minutes hands-on time.